Program
JSKN016HC
A development code.
Its studies are led by Alphamab Oncology.
Furthest: phase 1, since Mar 9, 20261 company-led study, 1 open or runningNext primary completion: Jul 1, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 11 open or running | phase 1since Mar 9, 2026 | Mar 9, 2026 | Jul 1, 2028phase 1 · NCT07475559 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 9, 2026First study: phase 1 study in Advanced Solid Tumor MalignanciesFirst studyNCT07475559 · 42 planned · Australia
Ahead
- Jul 1, 2028Primary completion: phase 1 study in Advanced Solid Tumor MalignanciesNCT07475559
TargetBeta
“JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07475559Advanced Solid Tumor Malignancies · Australia | 1 | Not yet recruiting | Jul 1, 2028 | 42 |
How it is read
Names in the registry
- “JSKN016HC”, 1 entry
Codes read as this program: JSKN016HC.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.